ARCHIVES

Holden Center At U. Of Iowa Designated Comprehensive.

This article is from The Cancer Letter archive.

Vol. 27 No. 04 | January 26, 2001

Download PDF Visit The Full Archive

Related Articles

AGS-003 Immunotherapy Induces T Cell Responses in Phase II Trial

November 29, 2013

Drug Cleared For GIST And Kidney Cancer, FDA’s First Two-Indication Cancer Approval

January 27, 2006

NCI Considers Seeking New Study Section For Clinical Research, Or Expansion Of E2

November 23, 1990

Clinical Trials: NCI Issues Clinical Alert On Chemo For Cervical Cancer

February 26, 1999

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

December 25, 2009

In Brief: Michael Grever Named DCT Deputy Director; MSK’s Burton Lee New White House Physician

March 31, 1989